

CORRIGENDUM

Down-Regulation of USP8 Suppresses HER-3 Positive Gastric Cancer Cells Proliferation [Corrigendum]

Sun J, Shen D, Gao Y, et al. *Onco Targets Ther.* 2020;13:7973–7984.

The authors apologize for this error and advise it does not affect the results of the paper.

The authors have advised due to an error at the time of figure assembly, Figure 3 on page 7980 is incorrect. The correct Figure 3 is shown below.

Dovepress Sun et al




Figure 3 Down-regulation of USP8 promotes the degradation of HER-3. (A) Different concentrations of USP8 inhibitor in MGC-803 and si-USP8 cells were used as the control group. (B) Different concentrations of USP8 inhibitor and si-USP8 in NCI-N87, MKN-45 and AGS cells. (C) mRNA level of HER-3 in NCI-N87, AGS and MKN-45 cell lines with USP8 inhibitor and si-USP8 treatment. Expression of HER-3 in NCI-N87 cells with the treatment of USP8 inhibitor (D) and si-USP8 (E) and cycloheximide (CHX, 20 µg/mL) in combination or alone. Expression of HER-3 in MKN-45 cells with the treatment of USP8 inhibitor (F) and si-USP8 (G) and CHX (20 µg/mL) in combination or alone. *P<0.05, **P<0.01. Abbreviation: NS, no statistical significance.

OncoTargets and Therapy

Publish your work in this journal

OncoTargets and Therapy is an international, peer-reviewed, open access journal focusing on the pathological basis of all cancers, potential targets for therapy and treatment protocols employed to improve the management of cancer patients. The journal also focuses on the impact of management programs and new therapeutic agents and protocols on patient perspectives such as quality of life, adherence and satisfaction. The manuscript management system is completely online and includes a very quick and fair peer-review system, which is all easy to use. Visit http://www.dovepress.com/ testimonials.php to read real quotes from published authors.

Submit your manuscript here: https://www.dovepress.com/oncotargets-and-therapy-journal



Dovepress